JCO Article Insights: Simultaneous Durvalumab and CRT in Unresectable Stage III NSCLC

<p>In this episode of JCO Article Insights, host Dr. Ece Cali Daylan interviews author Dr. Jeffrey Bradley about the article, "<a href="https://ascopubs.org/doi/10.1200/JCO-25-00036" target= "_blank" rel="noopener">Simultaneous Durvalumab and Chemoradiotherapy in Unresectable Stage III Non–Small Cell Lung Cancer</a>" by Bradley, et al published October 13, 2025.</p> <p><span style= "text-decoration: underline;"><strong>TRANSCRIPT</strong></span></p> <p dir="ltr">Dr. Ece Cali: Welcome to this episode of <a href= "https://ascopubs.org/journal/jco/podcast">JCO Article Insights</a>. This is Dr. Ece Cali, <a href= "https://ascopubs.org/journal/jco">JCO</a> Editorial Fellow. Today I'm joined by Dr. Jeffrey Bradley, Professor of Radiation Oncology at the University of Pennsylvania, to discuss the manuscript, "<a href= "https://ascopubs.org/doi/10.1200/JCO-25-00036">Simultaneous Durvalumab and Platinum-Based Chemoradiotherapy in Unresectable Stage III Non-Small-Cell Lung Cancer: The Phase III ...